Introduction
IL-18, primarily produced by macrophages and dendritic cells, was initially described as an IFN-g-inducing factor. 1 This cytokine serves as a cofactor for IL-12-induced development of Th1 immune response and optimizes IFN-g production from effector Th1 cells. 2 It plays a critical role in the development of protective immunity against intracellular pathogens such as Leishmania major, Mycobacterium tuberculosis, Cryptococcus neoformans, and Listeria monocytogenes. [3] [4] [5] [6] However, administration of IL-18 alone reportedly results in deviation of immune responses to Th2 type in mouse models of helminth infection and allergic asthma with enhanced IgE response. 7, 8 NK, T cells and basophils stimulated with IL-18 have been shown to generate Th2-type cytokines such as IL-4 and IL-13 when cultured together with IL-2 and IL-3, respectively. 7, 9 BALB/c mice are susceptible to infection with L. major, an intracellular protozoan parasite, with a Th2-type immune response resulting in progressive infection with a fatal outcome. 10 According to combined treatment with recombinant IL-18 and IL-12, however, those mice acquire potent protective immunity to ameliorate the infection by inducing and activating Th1-type response. In contrast, treatment with rIL-18 alone does not induce a Th1 response but rather exacerbates the disease by skewing the immune responses toward a Th2 type. 3, 11 
IL-18
À/À mice with a genetically resistant C57BL/6 background are relatively susceptible to infection with L. major, although the disease is finally controlled. 12 Thus, IL-18 has been supposed to contribute to the host defense synergistically with IL-12 by accelerating the development of Th1 response through augmentation of IFN-g production, but not always to be essential for development of Th1-type protective immunity.
In the present study, we found that gene therapy of susceptible BALB/c mice with an IL-18-expressing plasmid alone using a gene gun directs their immune responses to a Th1 type and prevents development of the disease, at a similar level as that induced by the IL-12 gene against L. major infection. This result is in clear contrast to that obtained using rIL-18 alone. We also investigated the molecular mechanisms underlying the difference between protective potentials of recombinant and plasmid encoded IL-18. The cytokine gene appears to play an important role in enhancement of IL-12 mRNA expression resulting in improving pathogenic process with support of the signaling pathway, especially through TLR9 activated by CpG motifs, which are included in the plasmid vector used in the gene therapy.
Results
Effect of IL-18 gene therapy in L. major-infected BALB/c mice Previous studies demonstrate that rIL-18 cannot protect BALB/c mice against L. major infection. 3 In the present study, experiments were carried out to determine whether treatment of BALB/c mice with an IL-18-expressing plasmid, pCAGGS-IL-18 (pIL-18) (Figure 1a) , exerts a therapeutic effect on L. major infection. As shown in Figure 1b , footpad swelling was significantly suppressed in pIL-18-treated mice compared with that in the untreated BALB/c mice (Po0.05 at 2-6 weeks after infection). The lesion size was similar to that in mice delivered with pIL-12 and, surprisingly, also similar to that in mice treated with pIL-12 plus pIL-18. No therapeutic effect was observed in mice that received a control plasmid vector alone. We also examined the parasite burden at 6 weeks after infection. Consistent with the results of footpad swelling, pIL-18-treated mice showed a markedly lower parasite burden in draining lymph nodes (LNs) than did control BALB/c mice ( Figure 1c ). These results indicate that gene therapy of mice with the IL-18-expressing plasmid induces protective immunity against L. major to a degree similar to that induced by IL-12 gene therapy.
To confirm whether resistance acquired by IL-18 gene therapy is mediated by the induction of a Th1 response, cytokine profiles were measured at 3 weeks after infection (Figure 1d ). Production of IFN-g and IL-4 by CD4 þ T cells from draining LNs was assessed after in vitro stimulation with L. major antigen. CD4 þ T cells from mice treated with pIL-18 generated a significantly greater amount of L. major-specific IFN-g than did those from mice treated with a control plasmid, which suffered from progressive disease (Po0.05). The amount of IL-4 produced was less in mice treated with pIL-18 than that in mice treated with control plasmid, although rIL-18 is known to promote IL-4 production. 7, 8 Similar results were also obtained at the mRNA level (data not shown). Thus, the IL-18 gene therapy appears to skew immune responses in a Th1 direction following L. major infection in BALB/c mice.
Requirement of IFN-g and TNF-a from Th1-type CD4 þ
T cells for protection conferred by pIL-18
To elucidate the mechanism by which IL-18 gene therapy confers protection against infection, mice were adminis- and those mice showed greater footpad swelling than did PBS-administered mice (Po0.05 at 3-6 weeks after infection). Cytotoxic activity and IFN-g production by NK cells were also significantly increased in pIL-18-treated mice (data not shown), a finding that is consistent with previously reported results. 13 However, the protective potential was not cancelled in mice depleted of NK cells by anti-asialo GM1 Ab, suggesting that NK cells are not the main effectors for the protection acquired by IL-18 gene therapy.
In addition to the increased IFN-g production, mice treated with pIL-18 also showed a markedly elevated level of TNF-a at 3 weeks after infection (Figure 1d ). TNF-a is one of the main cytokines involved in production of nitric oxide (NO), 14 and we therefore tried to clarify the significance of this cytokine in pIL-18-induced protection. Following IL-18 gene therapy, TNFa-deficient BALB/c mice generated remarkably high levels of IFN-g despite the fact that those mice acquired little protection against the infection (Figure 2b and c). Thus, TNF-a as well as IFN-g is required for protection induced by IL-18 gene therapy.
Essential role of endogenous IL-12 in protection conferred by pIL-18
IL-12 plays a critical role in IFN-g production synergistically with IL-18.
2. As shown in Figure 3a , quantitative real-time PCR revealed that IL-18 gene therapy increased the level of IL-12 p40 mRNA expression in L. majorinfected BALB/c mice. The role of IL-12 was investigated by using IL-12 p40-deficient mice. The KO mice were infected with L. major and treated with pIL-18. All of the KO mice showed susceptible phenotypes ( Figure 3b ). IFN-g secretion in popliteal LN cells of the KO mice was profoundly impaired compared with that in popliteal LN cells of wild-type (WT) mice despite the fact that IFN-g production was about 5-fold higher in IL-12 p40-deficient mice treated with pIL-18 than in mice treated with the control plasmid vector (Figure 3c ). Quantitative PCR analysis of cytokine mRNA showed similar results (data not shown). These results demonstrated that endogenous IL-12 is necessary for the IL-18 gene therapy, although an alternative IL-12-independent pathway seems to exist in IFN-g production.
Contribution of the plasmid backbone to induction of resistance to L. major infection by pIL-18
It is well known that treatment of L. major-infected mice with rIL-18 alone does not lead to control of the infection but, rather, exacerbates the disease. 3, 11 As shown in the present study, however, treatment of mice with a plasmid encoding IL-18 gene is markedly protective. We hypothesized that the difference in protective potentials of pIL-18 and rIL-18 is attributed to the plasmid vector contained in pIL-18, since the vector alone induced production of a significant amount of IL-12 after infection with L. major (Figure 3a) . To confirm this possibility, we injected rIL-18 into L. major-infected BALB/c mice over a period of 7 days with or without delivery of an empty plasmid vector. Footpad lesions in mice treated with rIL-18 progressed more than did those in untreated BALB/c mice. In contrast, mice treated with rIL-18 plus the plasmid vector acquired a similar degree of resistance as that of mice treated with pIL-18 ( Figure 4a ). 
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Parasite burden in draining LNs was also significantly decreased by this combined treatment (Figure 4b) . Administration of mice with rIL-18 augmented IL-4 production and did not influence IFN-g production. Notably, addition of the plasmid vector reversed the Th2 cytokine profile to Th1 (low IL-4 and high IFN-g) ( Figure  4c ). However, the treatment with pIL-18 appears to have more advantage than that with rIL-18 plus vector. That is, a weekly delivery system was enough in the former, while a daily treatment system was required in the latter. It is probably due to the low dose but long duration of cytokine secretion caused by the cytokine gene in vivo.
Induction of IL-12 through TLR9 ligation with CpG motifs in the plasmid vector
Thus, resistance conferred by pIL-18 was dependent on both exogenous IL-18 and endogenous IL-12 induced by the plasmid structure. We next analyzed the molecular mechanisms of IL-12 induction. Quantitative PCR promastigotes to the hind footpad, the mice were treated with rIL-18 daily for the first 7 days and/or an empty vector pCAGGS weekly from the day of infection (n ¼ 7/group). Severity of infection was assessed by monitoring footpad swelling weekly (a) and parasite burden at 6 weeks after infection (b). Cytokine production was analyzed as described in the legend to Figure  1d (c). Figure 5a ). The most likely candidate is CpG motifs because the plasmid used in this study had the structure that stimulates APCs to produce IL-12. Since CpG DNA transduces signals through TLR9, 15 we examined the IL-12-inducing ability of CpG motifs in our gene gun-delivery system by using TLR9 À/À mice. Further, TLR4
IL-
À/À mice were employed as the reference since previous study reported that TLR4 À/À mice responded normally to CpG. 16 PIL-18 was delivered to these KO mice or wild-type C57BL/6 mice, and IL-12 p40 mRNA expression in APCs was examined. Two-to three-fold increased level of IL-12 was detected in WT and TLR4
À/À mice but not in TLR9 À/À mice (Figure 5b) . A similar result was also obtained in mice delivered with an empty plasmid vector (data not shown). Thus, CpG motifs included in pIL-18 appear to play an essential role in induction of a Th1 response in L. major-infected BALB/c mice.
Confirmation of CpG motif contribution to induction of protective immunity
Immunostimulatory activity of bacterial DNA is attributed to the presence of unmethylated CpG motifs, and methylated CpG motifs show an inhibitory effect on immune activation induced by unmethylated CpG. 17 Then, we confirmed the function of CpG directly by using methylated plasmid containing CpG motifs. Treatment with rIL-18 plus unmethylated vector, again, improved pathogenic process as evaluated by either footpad swelling or parasite burden in the draining LNs (Figure 6a and b) , whereas, in treatment with methylated vector the effect was lost (Figure 6a and b) , and the Th1-type cytokine profile was reversed to Th2 type (Figure 6c ).
Discussion
In murine leishmaniasis models, treatment of genetically susceptible BALB/c mice with rIL-18 is reportedly therapeutic only when rIL-12 is coadministrated, while treatment with rIL-18 alone exacerbates the disease and enhances Th2 responses. 3 Interestingly, we found that gene therapy using an IL-18-expressing plasmid alone could render susceptible BALB/c mice resistant to the 2 Then, IL-12 and IL-18 activate STAT4 and activator protein-1 (AP-1), respectively, resulting in enhanced transcription of IFN-g mRNA. 18 On the other hand, treatment of mice with rIL-18 alone induces CD40L expression and production of IL-4 and IgE to promote Th2 responses. 2, 7, 8 NKT cells might be the major source to secrete IL-4 in response to IL-18 administration as we reported recently. 19 We show here that gene therapy with pIL-18 alone is enough to induce Th1-type protective immunity similar to that with IL-12 gene in BALB/c mice infected with L. major (Figure 1 ), suggesting that an additional factor(s) in the plasmid vector of pIL-18 may promote Th1-dependent protective immunity during L. major infection synergistically with IL-18 in vivo. Notably, delivery of pIL-18 augmented the expression of IL-12 p40 mRNA, but rIL-18 administration did not (Figures 3a  and 5a ). To confirm the role of IL-12, IL-12 p40-deficient mice were employed (Figure 3 ). Our results demonstrate that endogenous IL-12 is essential for the development of Th1-type protective immunity initiated by pIL-18.
Next, we addressed the issue of how pIL-18 induces endogenous IL-12. CpG motifs contained in the plasmid vector appear to play a key role in the difference between the therapeutic efficacies with pIL-18 and rIL-18 since CpG motifs have a capacity to elicit IL-12 production from APC via TLR9. CpG motifs are bacterial DNA sequences containing repeats of unmethylated C and G, which is a pathogen-associated molecular pattern recognized by TLR9. 20 The recognition of CpG motifs by TLR9 induces activation of signaling cascades such as c-Jun Nterminal kinase (JNK) and NF-kB. Expression of TLR9 is essential for CpG to induce NF-kB, which finally activates the IL-12 p40 promoter. [20] [21] [22] Notably, methylated CpG motifs lose the ability in immune stimulation. 20 We confirmed the necessity of the CpG-TLR9 pathway by using TLR9 À/À mice ( Figure 5 ) and the methylated plasmid ( Figure 6 ).
Adjuvant activity of CpG DNA has become well established in vaccination with various antigenic proteins and in DNA vaccination. [23] [24] [25] A large amount of CpG-ODN is known to confer protection against L. major infection with promotion of IL-12 production and expression of IL-12Rb2-chains, even in the absence of a specific antigen. 26 Elimination of CpG motifs from plasmid markedly reduces the efficiency of intramuscular DNA vaccination. 27 In our gene gun-mediated delivery system, administration of the empty plasmid vector alone did not result in amelioration of the disease, probably owing to the small quantity of CpG DNA delivered by a gene gun. That is, the quantity of DNA administered by the ballistic route is about 100-fold smaller than that in the case of intramuscular injection. 28 Interestingly, however, the small amount of CpG motifs was sufficient to trigger Th1 responses when rIL-18 was coadministered.
The amount of TNF-a was elevated in mice treated with pIL-18 ( Figure 1d ). IL-18 induces TNF-a production through the activation of NF-kB. 29 Neutralization of IL-18 results in a decrease of TNF-a production in lethal endotoxemia as well as in the cornea infected with Pseudomonas aeruginosa. 29, 30 Administration of TNF-a at a therapeutic dose leads to an amelioration of symptoms in susceptible mice, whereas resistant C57BL/6 mice lacking TNF rapidly succumb to progressive leishmaniasis. 31, 32 TNF-a À/À BALB/c mice showed high susceptibility to L. major infection even when a substantial amount of IFN-g was generated in those KO mice treated with pIL-18 ( Figure 2) . Thus, TNF-a, in addition to IFN-g, was shown to be necessary for the development of protective immunity against L. major infection.
In conclusion, the present study demonstrated that gene therapy with an IL-18-expressing plasmid alone improves pathogenic process in L. major-infected BALB/c mice without the requirement of exogenous IL-12, ameliorating disease-progressive Th2 responses to protective Th1 responses. CpG motifs included in the delivered plasmids appear to play a key role in developing Th1 responses through the production of proinflammatory cytokines, especially IL-12, at the APC level via TLR9 ligation.
Materials and methods

Animals and parasites
Studies using mice were performed in accordance with the institutional guidelines of Kyushu University. Female BALB/cN Sea (BALB/c), DBA/2N Sea (DBA/2) and C57BL/6N Sea (B6) mice were purchased from Seac Yoshitomi (Fukuoka, Japan). TNF-a À/À mice were generated as described previously 33 and backcrossed onto the BALB/c background. IL-12 p40-deficient mice on the C57BL/6 background were kindly provided by Dr J Magram (Hoffmann-LaRoche, Nutley, USA).
Generation of TLR4
À/À and TLR9 À/À mice has been described previously. 15, 34 All mice were housed under specific pathogen-free conditions. Sex-and age-matched (8-12 week old) mice were used in all experiments.
L. major (MHOM/SU/73-5-ASKH) was maintained by serial passages in the footpads of BALB/c mice. Promastigotes harvested from stationary-phase cultures were inoculated into the left hind footpad of each mouse.
Reagents
Mouse anti-CD4 (GK1.5). and anti-IFN-g (R4-6A2) mAbs were purified from ascites. Anti-asialo GM-1 polyclonal serum was purchased from Wako Chemicals (Osaka, Japan). Mouse rIL-18 was obtained from Medical & Biological Laboratories (Nagoya, Japan). ELISA Development Kits for IFN-g and IL-4 were purchased from Genzyme Techne (Minneapolis, MN, USA). FITC-conjugated anti-CD4 antibody was purchased from BD Pharmingen (San Diego, CA,USA). Anti-FITC Microbeads were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). CpG methylase (M. SssI) was obtained from New England Biolabs (Beverly, MA, USA).
IL-18 gene therapy for leishmaniasis
Y Li et al
Cytokine-expressing plasmids
An IL-18-expressing plasmid, designated pCAGGS-IL-18, was constructed by inserting the mouse IFN-b signal sequence and mature mouse IL-18 cDNA (a gift from Dr I Hara, Kobe University, Japan) 35 into the unique EcoRI site between the CAG promoter and a 3'-flanking sequence of the rabbit b-globin gene of the pCAGGS expression vector (a gift from Dr J Miyazaki, Osaka University, Japan) (Figure 1a ). An IL-12-expressing plasmid, designated pCAGGS-IL-12, was constructed as described previously. 36 The plasmids were replicated in Escherichia coli DH5a and purified using the QIAGEN Plasmid Kit Maxi or Mega (QIAGEN, Chatsworth, CA, USA).
Treatment protocol
A Helios Gene Gun (Bio-Rad, Hercules, CA, USA) was used for gene therapy as described previously. 36 Briefly, plasmid DNA was precipitated onto gold particles 1.6 mm in diameter and coated onto the inner face of the tubing by a tube loader. The final tubing segment resulted in delivery of 0.125 mg of gold particles and 2 mg of plasmid DNA. Administration of two nonoverlapping shots (total 4 mg of DNA) per mouse into freshly shaven abdominal skin at a helium pressure of 300 psi was started on day 0 after the infection and repeated weekly. In some experiments, in order to deplete CD4 þ T cells and NK cells, 0.5 mg of anti-CD4 mAb or 100 mg of antiasialo GM-1 polyclonal serum was injected intraperitoneally (i.p.) into the mice on days À1, 3, 7, 10, 14, 21 and 28 after infection. Over 95% of the cells of each corresponding subset was invariably found to be deleted. Anti-IFNg mAb was administered with the same schedule. In some experiments, mice were injected intraperitoneally each day with 1 mg of rIL-18 for the first 7 days after L. major infection with or without delivery of the plasmid vector.
Determination of lesion size and parasite burden
Footpad lesion size was measured weekly with a dial caliper and expressed as the difference in thickness between the infected footpad and uninfected contralateral footpad. To determine the number of viable L. major parasites in the tissues of infected mice, draining popliteal lymph nodes (LNs) were obtained from mice 6 weeks after infection. The LNs were homogenized by slide glass. Then, cells were washed twice with Medium 199, plated at a concentration of 10 6 per 2 ml Medium 199 containing 10% FBS in 12-well tissue plates and cultured at 251C. The number of parasites was counted using a microscope 7 days later. Parasite burden was expressed as the number of parasites per LN.
Cytokine production
Draining LNs were obtained from mice of each group at 3 or 6 weeks after infection. The nodes from a minimum of three mice in each group were pooled and then purified into CD4 þ T-cell subpopulations using Magnetic Separation Columns (Miltenyi Biotec, Germany). Flow cytometry confirmed 4 95% purity of CD4 þ T lymphocytes. The cells were then plated in a 96-well microtiter plate at 2.5 Â 10 5 cells per 200 ml RPMI1640 supplemented with 10% FBS, with or without L. major antigen obtained from freeze-thawed promastigotes, in the presence of irradiated (30 Gy) splenocytes. Culture supernatants were harvested 72 h later, and cytokine concentration was determined by sandwich ELISA.
Analysis of mRNA expression
APCs were collected from spleen or LN as plasticadherent cells as described. 37 . Mainly macrophages were separated in this case. Total RNA was prepared from these cells and was reverse-transcribed with SuperScript II (Takara Biomedicals, Tokyo, Japan). Primer sequences for IFN-g and IL-4 have been described previously. 38 The primer sequences for IL-12 p40 are 5 0 -AAC CTC ACC TGT ACA CGC C-3 0 (sense) and 5 0 -CAA GTC CAT GTT TCT TTG CAC G-3 0 (antisense). Quantitative real-time PCR was performed using an ABI Prism 7700 Sequence Detector System (P.E. Biosystems, Warrington, GB). Results are expressed as n-fold difference relative to the expression of b-actin.
DNA methylation
Full CpG methylation of plasmid was performed with SssI methylase 39 according to the manufacturer (New England Biolabs). Briefly, methylation of every 100 mg of plasmid DNA was conducted by incubation with 30 U SssI in 500 ml buffer, 640 mM S-adenosylmethionine, for 2 h at 371C. Complete methylation was verified by extensive digestion with the methylation sensitive restriction enzyme BstUI.
Statistical analysis
Data are expressed as mean7s.d. Differences between experimental groups in each experiment were analyzed by using Student's t-test and were considered significant if Po0.05.
